For decades, checking blood sugar meant the same routine: a lancet, a test strip, a drop of blood, and a number that told you nothing about what happened an hour ago or what might happen next. That ...
DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...
Insulet (PODD) stock and DexCom (DXCM) receive new Buy ratings from Deutsche Bank while Tandem Diabetes Care (TNDM) stock ...
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...
Smartwatches may transform blood sugar tracking, but today’s advances depend on CGMs, AI, and regulated health tech ...
Continuous glucose monitors have become popular among those who need to track their glucose levels because they're painless ...
AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...
FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, ...
Dexcom is transforming its Stelo CGM into a whole-family wellness device, securing FDA clearance for pediatric use and debuting new AI tools.
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...
Over-the-counter continuous glucose monitors have gained popularity over recent years. These devices are designed to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results